A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

NCT02356562 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG: ombitasvir/paritaprevir/ritonavir and dasabuvir
DRUG: Sofosbuvir
DRUG: Ribavirin

Sponsor

AbbVie